Why do some cancers respond well to checkpoint inhibitors while 'cold' tumors don't, and what strategies are being tried

Checkpoint inhibitors (such as anti-PD-1 or anti-CTLA-4 therapies) work by "taking the brakes off" the immune system. They rely on the presence of T-cells that have already recognized cancer cells but have been turned off by inhibitory signals.

Why some tumors respond ("Hot" vs. "Cold")

• "Hot" (Inflamed) tumors: These tumors have already been infiltrated by T-cells. Because the immune system is actively trying to attack the tumor, the cancer often develops "checkpoints" to suppress these cells. Checkpoint inhibitors release this suppression, allowing existing T-cells to resume their attack.
• "Cold" (Non-inflamed) tumors: These tumors lack significant T-cell infiltration. They are often "invisible" to the immune system due to a lack of tumor antigens (mutations the immune system can recognize), or they create a physical and chemical barrier—such as dense connective tissue or an immunosuppressive environment—that prevents T-cells from entering or surviving. Because there are no T-cells present to be "unleashed," checkpoint inhibitors have little effect.

Strategies to turn "Cold" tumors "Hot"

Researchers are working to prime these tumors so that the immune system can see and infiltrate them:

1. Oncolytic Viruses: These are engineered viruses designed to infect cancer cells and cause them to burst (lyse). This releases tumor antigens and triggers inflammation, which acts as a "flare" to recruit T-cells to the site.
2. Chemotherapy and Radiation: Used in specific, low, or localized doses, these treatments can damage cancer cells in a way that promotes "immunogenic cell death." This process alerts the immune system to the presence of the cancer.
3. Targeting the Microenvironment: Some treatments aim to break down the physical barriers surrounding the tumor or neutralize immunosuppressive cells (like myeloid-derived suppressor cells or regulatory T-cells) that prevent effector T-cells from entering.
4. Bispecific Antibodies: These act like a bridge, with one arm grabbing onto a T-cell and the other grabbing onto the cancer cell, physically forcing the two together to initiate an immune response.
5. Cancer Vaccines: Some experimental vaccines aim to teach the immune system to recognize specific markers on a patient’s unique tumor, effectively creating the T-cells required for a checkpoint inhibitor to be effective later.
6. Combination Therapies: Often, researchers combine checkpoint inhibitors with agents that induce an initial immune response, hoping that the "inflamed" state created by the first treatment allows the checkpoint inhibitor to do its job.

The goal of all these strategies is to increase the presence of tumor-infiltrating lymphocytes (TILs), transforming the tumor into an environment where the immune system can successfully recognize and destroy the malignant cells.